Literature DB >> 18714165

Multifocal Epstein-Barr virus-associated smooth muscle tumor in adults with AIDS: case report and review of the literature.

S Gallien1, B Zuber, M Polivka, M Lagrange-Xelot, J-B Thiebault, P Bertheau, F Gray, J-M Molina.   

Abstract

OBJECTIVES: The aim of this study was to provide a systematic review of Epstein-Barr virus-associated smooth muscle tumors (EBV-SMT) in human immunodeficiency virus (HIV)-infected adults, focusing on clinical and histopathologic features and outcome.
METHODS: A literature search was performed using Medline, Embase and the Cochrane Library.
RESULTS: We reviewed 35 cases including our case of a patient with a progressive multifocal EBV-SMT. Patients were mainly men (n = 24) with a mean age of 35.5 years. Median CD4 count was 21/mm(3). Main locations were brain (n = 12), liver (n = 8), spinal cord (n = 7) and adrenal gland (n = 6). The tumors were multifocal in 34% of cases, whereas analysis of clonality showed different clones in tumors from different sites. Treatment included removal surgery in 17 cases and/or radiotherapy in 9 and therapeutic abstention in 4. Mean follow-up after diagnosis was 12.3 months. Nine patients died during this period essentially from opportunistic infection and only 2 from the disease.
CONCLUSION: EBV-SMT should be added to the list of virally induced tumors in severely immunocompromised HIV-infected adults. Multifocality of independent tumor clones, especially in liver, brain, spinal cord and adrenal gland, and a slow disease progression seem to be the key features of these tumors, the treatment of which remains poorly defined. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714165     DOI: 10.1159/000151364

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency.

Authors:  Rachel K Shaw; Andrew C Issekutz; Robert Fraser; Pierre Schmit; Barb Morash; Linda Monaco-Shawver; Jordan S Orange; Conrad V Fernandez
Journal:  Blood       Date:  2012-03-16       Impact factor: 22.113

Review 2.  Multicentric hepatic EBV-associated smooth muscle tumors in an AIDS patient: a case report, investigation of mTOR activation and review of the literature.

Authors:  Qi Shen; Wei Feng; Michael S Long; Xiuzhen Duan; Siraya Jaijakul; Cesar A Arias; Robert E Brown; Bihong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2011-04-23

3.  Clinical history of HIV infection may be misleading in cytopathology.

Authors:  Liron Pantanowitz; Michael Kuperman; Robert A Goulart
Journal:  Cytojournal       Date:  2010-06-12       Impact factor: 2.091

4.  Epstein Barr virus associated smooth muscle tumors in the central nervous system: a case report and systematic review of the literature.

Authors:  V M Willeke; M P Anderson; A Mahadevan; R Rojas; R Bhadelia; A J Thomas; E M Kasper
Journal:  J Neurooncol       Date:  2020-03-05       Impact factor: 4.130

5.  AIDS-Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases.

Authors:  Bibianna Purgina; Uma N M Rao; Markku Miettinen; Liron Pantanowitz
Journal:  Patholog Res Int       Date:  2011-03-10

6.  Soft tissue mass at the infrascapular fossa.

Authors:  Seng-Choe Tham; Andrew E Horvai; Thomas Link; Lynne Steinbach
Journal:  Skeletal Radiol       Date:  2010-04-14       Impact factor: 2.199

7.  Role of surgery in treating epstein-barr virus-associated smooth muscle tumor (EBV-SMT) with central nervous system invasion: A systemic review from 1997 to 2019.

Authors:  Ka-Wei Lau; Yu-Wei Hsu; Yin-Ting Lin; Ko-Ting Chen
Journal:  Cancer Med       Date:  2021-02-11       Impact factor: 4.452

8.  Multifocal EBV-associated smooth muscle tumors in a patient with cytomegalovirus infection after liver transplantation: a case report from Shiraz, Iran.

Authors:  Mohammad Hossein Anbardar; Neda Soleimani; Dornaz Safavi; Ahad Eshraghian; Abbas Ayoub
Journal:  Diagn Pathol       Date:  2022-01-07       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.